Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LY3475070 |
Synonyms | |
Therapy Description |
LY3475070 is a CD73 inhibitor, which inhibits conversion of adenosine monophosphate (AMP) to adenosine to prevent suppression of the anti-tumor response (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY3475070 | LY-3475070|LY 3475070 | Adenosine Targeting 23 | LY3475070 is a CD73 inhibitor, which inhibits conversion of adenosine monophosphate (AMP) to adenosine to prevent suppression of the anti-tumor response (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04148937 | Phase I | LY3475070 LY3475070 + Pembrolizumab | A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer | Completed | USA | GBR | AUS | 0 |